SCHEMBL10178034

SCHEMBL10178034

CC(C)(C)OC(=O)n1c(=O)c(CBr)cn([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)c1=O

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 6/20 0.37
HDAC1 Q13547 6/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10178012 1.00 TOP2A (0.37) TOP2AHDAC1
SCHEMBL12762680 1.00 TOP2A (0.37) TOP2AHDAC1
SCHEMBL10178214 0.91 TOP2A (0.30) TOP2A
SCHEMBL16728051 0.91 TOP2A (0.30) TOP2A
SCHEMBL889603 0.91 TOP2A (0.30) TOP2A
SCHEMBL12570200 0.89 TOP2A (0.41) TOP2AHDAC1
SCHEMBL12762679 0.89 TOP2A (0.41) TOP2AHDAC1
SCHEMBL17476052 0.89 TOP2A (0.41) TOP2AHDAC1
SCHEMBL17466588 0.86
SCHEMBL889667 0.80 TOP2A (0.34) TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10697009-B2 Nucleotide analogs for sequencing IBIS BIOSCIENCES INC. (US) 2020-06-30 US disclosed
US-10428379-B2 Nucleotide analogs for sequencing IBIS BIOSCIENCES, INC. (US) 2019-10-01 US disclosed
EP-2970366-B1 NUCLEOTIDE ANALOGS FOR SEQUENCING IBIS BIOSCIENCES INC (US) 2019-01-16 EP disclosed
US-20160032376-A1 NUCLEOTIDE ANALOGS FOR SEQUENCING IBIS BIOSCIENCES, INC. 2016-02-04 US disclosed
US-9023316-B2 Synthesis of 18F-labeled tracers in hydrous organic solvents SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2015-05-05 US disclosed
US-8148503-B2 Nucleotides and nucleosides and methods for their use in DNA sequencing LASERGEN, INC. (US) 2012-04-03 US disclosed
US-7964352-B2 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing LASERGEN, INC. (US) 2011-06-21 US disclosed
US-20100041041-A1 NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING AGILENT TECHNOLOGIES, INC. 2010-02-18 US disclosed
US-20090081686-A1 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING AGILENT TECHNOLOGIES, INC. 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041041-A1 NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING UNG, NT5C2, NT5E TOP2A 117/4885HDAC1 4499/4885
US-10428379-B2 Nucleotide analogs for sequencing RNGTT, POLRMT, NT5C3B TOP2A 492/4885HDAC1 4875/4885
US-10697009-B2 Nucleotide analogs for sequencing RNGTT, POLRMT, NT5C3B TOP2A 492/4885HDAC1 4875/4885
US-20160032376-A1 NUCLEOTIDE ANALOGS FOR SEQUENCING RNGTT, POLRMT, NT5C3B TOP2A 492/4885HDAC1 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.